Ga-68 DPI-4452 PET/CT Shows High Sensitivity for ccRCC Detection
A prospective trial of 30 patients evaluated [68Ga]Ga-DPI-4452, a carbonic anhydrase IX-targeted PET/CT tracer, for identifying and staging clear cell renal cell carcinoma before surgery or biopsy. The trial reported 100% sensitivity and 85.7% specificity for detecting primary ccRCC, 97.7% sensitivity for extrarenal metastases, and detection of 82.6% more metastatic lesions than conventional imaging, with tracer uptake correlating with tissue CAIX expression (r=0.83, p<0.0001). No tracer-related adverse events were reported.
Most relevant for: Patients with suspected renal masses undergoing preoperative evaluation or staging for clear cell renal cell carcinoma.
Read the original at Journal of Nuclear MedicineSummary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.
Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.
Specialties
More nuclear medicine updates
- New PET-based method images Ac-225 therapy with higher SNR than SPECTSep 30, 2026
- Open-Source Deep Learning Pipeline Automates PET-Only Tumor SegmentationSep 30, 2026
- New PET tracer targets human CD68 to image macrophagesSep 28, 2026
- PSMA-PET detects more oligometastatic prostate cancer than conventional imagingSep 28, 2026
- Quantitative flow by CZT-SPECT predicts cardiovascular events independentlySep 25, 2026